StockData
BOLDNasdaqPharmaceutical PreparationsFiscal year ends December 31

Boundless Bio, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026
$2.31−0.03 (-1.28%)

Close on Oct 19, 2026

Market cap
$51.86M
P/E (TTM)
–
Dividend yield
–

SEC filings

32 of Boundless Bio's most recent filings on SEC EDGAR

DocumentFormPeriodFiledSource
Current report8-KAug 28, 2026Aug 28, 2026SEC EDGAR
Quarterly report10-QJun 30, 2026Aug 7, 2026SEC EDGAR
Current report8-KJun 22, 2026Jun 23, 2026SEC EDGAR
Current report8-KJun 15, 2026Jun 17, 2026SEC EDGAR
Quarterly report10-QMar 31, 2026May 8, 2026SEC EDGAR
Current report8-KMay 8, 2026May 8, 2026SEC EDGAR
Proxy statementDEF 14AJun 15, 2026Apr 28, 2026SEC EDGAR
Current report8-KApr 13, 2026Apr 13, 2026SEC EDGAR
Annual report10-KDec 31, 2025Mar 9, 2026SEC EDGAR
Current report8-KMar 3, 2026Mar 9, 2026SEC EDGAR
Quarterly report10-QSep 30, 2025Nov 5, 2025SEC EDGAR
Current report8-KNov 5, 2025Nov 5, 2025SEC EDGAR
Quarterly report10-QJun 30, 2025Aug 5, 2025SEC EDGAR
Current report8-KAug 5, 2025Aug 5, 2025SEC EDGAR
Current report8-KJun 23, 2025Jun 23, 2025SEC EDGAR
Current report8-KMay 23, 2025May 23, 2025SEC EDGAR
Quarterly report10-QMar 31, 2025May 9, 2025SEC EDGAR
Current report8-KMay 9, 2025May 9, 2025SEC EDGAR
Proxy statementDEF 14AJun 23, 2025Apr 29, 2025SEC EDGAR
Current report8-KApr 1, 2025Apr 1, 2025SEC EDGAR
Annual report10-KDec 31, 2024Mar 27, 2025SEC EDGAR
Current report8-KMar 27, 2025Mar 27, 2025SEC EDGAR
Current report8-KDec 6, 2024Dec 12, 2024SEC EDGAR
Quarterly report10-QSep 30, 2024Nov 7, 2024SEC EDGAR
Current report8-KNov 7, 2024Nov 7, 2024SEC EDGAR
Current report8-KOct 11, 2024Oct 15, 2024SEC EDGAR
Current report8-KAug 19, 2024Aug 20, 2024SEC EDGAR
Current report8-KAug 12, 2024Aug 12, 2024SEC EDGAR
Quarterly report10-QJun 30, 2024Aug 12, 2024SEC EDGAR
Quarterly report10-QMar 31, 2024May 13, 2024SEC EDGAR
Current report8-KMay 13, 2024May 13, 2024SEC EDGAR
Current report8-KApr 2, 2024Apr 2, 2024SEC EDGAR